Veeva Systems (NYSE:VEEV) Reaches New 12-Month High – Here’s Why

Veeva Systems Inc. (NYSE:VEEV) reached a new 52-week high on Tuesday. The company traded as high as $308.38 and last traded at $304.9830, with a volume of 182,412 shares. The stock had previously closed at $295.85.

Veeva Systems News Roundup

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Expanded IQVIA partnership: IQVIA selected Veeva’s Clinical Trial Management System, electronic trial master file, Study Startup and Site Connect applications as enterprise standards across its global clinical development studies. The agreement expands Veeva’s existing electronic data capture relationship, increases adoption of its broader clinical suite and could strengthen its competitive position in clinical-trial software. IQVIA Selects Veeva Clinical Operations Applications
• Positive Sentiment: Growing emerging-biotech footprint: More than 175 emerging biotechnology companies are reportedly using Veeva’s Basics suite, supporting a potential long-term customer pipeline as smaller drug developers adopt Veeva’s clinical, regulatory and quality tools early in their growth. Veeva Systems’ Basics Gains Traction With 175+ Emerging Biotech Firms
• Positive Sentiment: Technical momentum remains strong: The stock recently moved above a buy point in an early-stage chart pattern and reached a new 52-week high, indicating institutional demand and continued investor interest in Veeva’s AI and life-sciences software exposure. Veeva Stock Breaks Out As Big Money Grabs Exposure To The AI Software Play
• Neutral Sentiment: Veeva will hold a virtual investor day on November 5, where management may provide updates on strategy, growth opportunities and financial targets. The event could become a future catalyst, but no new guidance was provided in the announcement. Veeva to Host Virtual Investor Day
• Negative Sentiment: After climbing sharply and trading near its 52-week high, VEEV appears vulnerable to short-term profit-taking. Its valuation remains elevated, with a reported P/E ratio near 49, so investors may be demanding further evidence that the IQVIA expansion and Basics adoption will translate into sustained revenue growth.

Analyst Ratings Changes

VEEV has been the subject of several recent research reports. Needham & Company LLC increased their price objective on shares of Veeva Systems from $270.00 to $310.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Weiss Ratings raised shares of Veeva Systems from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Morgan Stanley upped their target price on shares of Veeva Systems from $215.00 to $275.00 and gave the company an “equal weight” rating in a research note on Thursday, August 27th. Royal Bank Of Canada upped their target price on shares of Veeva Systems from $275.00 to $325.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Finally, Mizuho raised their price target on shares of Veeva Systems from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Nineteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $284.88.

Veeva Systems Price Performance

The stock has a market cap of $48.12 billion, a PE ratio of 48.73, a P/E/G ratio of 1.29 and a beta of 0.93. The business has a fifty day moving average of $266.28 and a 200 day moving average of $206.24.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. The firm had revenue of $927.96 million during the quarter, compared to analyst estimates of $905.38 million. During the same quarter last year, the firm earned $1.99 EPS. Veeva Systems’s quarterly revenue was up 17.6% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, equities research analysts expect that Veeva Systems Inc. will post 6.70 EPS for the current year.

Insider Activity

In related news, Director Priscilla Hung sold 750 shares of Veeva Systems stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total value of $195,780.00. Following the completion of the sale, the director owned 3,242 shares in the company, valued at approximately $846,291.68. The trade was a 18.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel J. Rizzo sold 4,841 shares of the company’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $276.51, for a total transaction of $1,338,584.91. Following the completion of the sale, the executive vice president directly owned 7,665 shares in the company, valued at $2,119,449.15. This represents a 38.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 51,591 shares of company stock worth $13,355,945. 10.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. grew its stake in Veeva Systems by 7.0% during the 1st quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company’s stock worth $727,513,000 after buying an additional 271,252 shares during the last quarter. Swedbank AB increased its position in Veeva Systems by 43.5% in the first quarter. Swedbank AB now owns 1,645,128 shares of the technology company’s stock worth $288,983,000 after buying an additional 498,971 shares during the period. Pictet Asset Management Holding SA lifted its stake in Veeva Systems by 43.6% in the first quarter. Pictet Asset Management Holding SA now owns 1,593,795 shares of the technology company’s stock valued at $279,970,000 after buying an additional 483,720 shares during the last quarter. Amundi lifted its stake in Veeva Systems by 8.0% in the first quarter. Amundi now owns 992,977 shares of the technology company’s stock valued at $174,426,000 after buying an additional 73,510 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Veeva Systems by 203.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 913,281 shares of the technology company’s stock valued at $160,427,000 after buying an additional 611,868 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.